Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations

被引：3

作者：

Millen, Brian A. ^{[1
]}

Dmitrienko, Alex ^{[2
]}

Mandrekar, Sumithra J. ^{[3
]}

Zhang, Zongjun ^{[1
]}

Williams, Dominique ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

[2] Quintiles, Durham, NC USA

[3] Mayo Clin, Rochester, MN USA

来源：

THERAPEUTIC INNOVATION & REGULATORY SCIENCE | 2014年 / 48卷 / 04期

关键词：

subgroup analysis; tailored therapeutics; familywise error rate; influence condition; interaction condition; PRESPECIFIED SUBGROUP; BIOMARKER; TRASTUZUMAB; SIGNATURE;

D O I：

10.1177/2168479013519630

中图分类号：

R-058 [];

学科分类号：

摘要：

Several recent publications have focused on statistical considerations that arise in multipopulation tailoring clinical trials that evaluate treatment effect in an overall patient population as well as one or more predefined subpopulations. This paper presents a decision-making framework applicable to these trials and evaluates the operating characteristics of this framework versus one based solely on the results of primary hypothesis tests. The operating characteristics are presented as rates of applicable errors, known as influence errors and interaction errors.

引用

页码：453 / 462

页数：10

共 50 条

[1] Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations
Brian A. Millen
Alex Dmitrienko
Sumithra J. Mandrekar
Zongjun Zhang
Dominique Williams
[J]. Therapeutic Innovation & Regulatory Science, 2014, 48 : 453 - 462
[2] BAYESIAN ASSESSMENT OF THE INFLUENCE AND INTERACTION CONDITIONS IN MULTIPOPULATION TAILORING CLINICAL TRIALS
Millen, Brian A.
Dmitrienko, Alex
Song, Guochen
[J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (01) : 94 - 109
[3] A Statistical Framework for Decision Making in Confirmatory Multipopulation Tailoring Clinical Trials
Millen, Brian A.
Dmitrienko, Alex
Ruberg, Stephen
Shen, Lei
[J]. DRUG INFORMATION JOURNAL, 2012, 46 (06): : 647 - 656
[4] A Statistical Framework for Decision Making in Confirmatory Multipopulation Tailoring Clinical Trials
Brian A. Millen
Alex Dmitrienko
Stephen Ruberg
Lei Shen
[J]. Drug information journal : DIJ / Drug Information Association, 2012, 46 : 647 - 656
[5] Multiplicity considerations in the design and analysis of clinical trials
Cook, RJ
Farewell, VT
[J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 1996, 159 : 93 - 110
[6] Design and Analysis Considerations in Clinical Trials With a Sensitive Subpopulation
Zhao, Yan D.
Dmitrienko, Alex
Tamura, Roy
[J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (01): : 72 - 83
[7] CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF CLINICAL-TRIALS IN PERIODONTITIS - DISCUSSION
ONEILL, RT
[J]. JOURNAL OF CLINICAL PERIODONTOLOGY, 1986, 13 (05) : 529 - 532
[8] Design and analysis considerations for first treatment escalation in clinical trials
Wei, Wei
Dougados, Maxime
Bernasconi, Corrado
[J]. CONTEMPORARY CLINICAL TRIALS, 2021, 104
[9] STATISTICAL CONSIDERATIONS ON DESIGN AND ANALYSIS OF BRIDGING AND MULTIREGIONAL CLINICAL TRIALS
Tsong, Yi
[J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 1078 - 1080
[10] CLINICAL CONSIDERATIONS IN THE DESIGN OF CLINICAL-TRIALS
CARTER, SK
[J]. CANCER TREATMENT REPORTS, 1980, 64 (2-3): : 367 - 371

← 1 2 3 4 5 →